The estimated Net Worth of David Abraham is at least $272 Тысяча dollars as of 14 November 2017. David Abraham owns over 5,405 units of Selecta Biosciences Inc stock worth over $4,756 and over the last 8 years David sold SELB stock worth over $267,192.
David has made over 2 trades of the Selecta Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently David bought 5,405 units of SELB stock worth $49,996 on 14 November 2017.
The largest trade David's ever made was selling 14,844 units of Selecta Biosciences Inc stock on 21 December 2016 worth over $267,192. On average, David trades about 3,375 units every 55 days since 2016. As of 14 November 2017 David still owns at least 5,405 units of Selecta Biosciences Inc stock.
You can see the complete history of David Abraham stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL STREET, BUILDING ONE, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at Selecta Biosciences Inc have traded over $10,638,154 worth of Selecta Biosciences Inc stock and bought 37,612,684 units worth $162,669,477 . The most active insiders traders include Timothy A Springer, Advisors Llc Orbi Med Capit... и Carl L Gordon. On average, Selecta Biosciences Inc executives and independent directors trade stock every 23 days with the average trade being worth of $300,312. The most recent stock trade was executed by Carsten Brunn on 25 September 2023, trading 2,932 units of SELB stock currently worth $3,108.
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Selecta Biosciences Inc executives and other stock owners filed with the SEC include: